OPKO Health, Inc. Amount Recognized in Income Due to Inflationary Accounting
OPKO Health, Inc. (OPK) reported Amount Recognized in Income Due to Inflationary Accounting of $2.50 million for the 6-month period ending 2026-06-30, per its 10-Q/A filed 2026-08-28.
Financial Statements › Income Statement › Other Income
us-gaap:AmountRecognizedInIncomeDueToInflationaryAccounting · last filed 2026-08-28
- OPKO Health, Inc. amount recognized in income due to inflationary accounting for the quarter ending 2026-06-30 was $700.00K.
- OPKO Health, Inc. amount recognized in income due to inflationary accounting for the quarter ending 2026-03-31 was $1.80M.
- OPKO Health, Inc. amount recognized in income due to inflationary accounting for the quarter ending 2025-12-31 was -$8.30M.
- OPKO Health, Inc. amount recognized in income due to inflationary accounting for the quarter ending 2025-09-30 was $0.00.
- OPKO Health, Inc. amount recognized in income due to inflationary accounting for fiscal 2024 was $10.10M.
| Period end | Amount Recognized in Income Due to Inflationary Accounting 3 month | Amount Recognized in Income Due to Inflationary Accounting 6 month | Amount Recognized in Income Due to Inflationary Accounting 9 month | Amount Recognized in Income Due to Inflationary Accounting 12 month | Amount Recognized in Income Due to Inflationary Accounting 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $700.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2026-08-28 | $2.50M 10-Q/A · filed 2026-08-28 | -$5.80M derived: sum of 3 quarters · filed 2026-08-28 | -$5.80M derived: sum of 4 quarters · filed 2026-08-28 | |
| 2026-03-31 | $1.80M 10-Q/A · filed 2026-08-28 | -$6.50M derived: sum of 2 quarters · filed 2026-08-28 | -$6.50M derived: sum of 3 quarters · filed 2026-08-28 | ||
| 2025-12-31 | -$8.30M derived: 10-Q/A 12 month − 10-Q 9 month · filed 2026-08-28 | -$8.30M derived: sum of 2 quarters · filed 2026-08-28 | $1.80M 10-Q/A · filed 2026-08-28 | $10.10M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $10.10M 10-Q · filed 2025-10-29 | |||
| 2025-06-30 | $10.10M 10-Q · filed 2025-07-31 | ||||
| 2024-12-31 | $10.10M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |